MDxHealth

MDxHealth Equity

Delisted

The The Equity of MDxHealth (MDXH.BR) as of Nov 5, 2026 is -10.62 M USD. In the previous year, The Equity was 13.03 M USD — a change of -181.49% (lower).

Equity

-10.62 MUSD

YoY

-181.49%

Last updated:

In 2025, MDxHealth's equity was -10.62 M USD, a -181.49% increase from the 13.03 M USD equity in the previous year.

The MDxHealth Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
45.77 M USD
Jan 1, 2019
17.32 M USD
Jan 1, 2020
5.14 M USD
Jan 1, 2021
41.19 M USD
Jan 1, 2022
8.18 M USD
Jan 1, 2023
6.33 M USD
Jan 1, 2024
13.03 M USD
Jan 1, 2025
-10.62 M USD
The MDxHealth Equity history
YEAREquityYoY
-10.62 MUSD-181.49%
13.03 MUSD+105.90%
6.33 MUSD-22.62%
8.18 MUSD-80.14%
41.19 MUSD+701.83%
5.14 MUSD-70.35%
17.32 MUSD-62.15%
45.77 MUSD+19.68%
38.24 MUSD-17.43%
46.32 MUSD+19.16%
38.87 MUSD+86.16%
20.88 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MDxHealth Stock analysis

What does MDxHealth do? MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth is one of the most popular companies on Eulerpool.

Equity Details

Analyzing MDxHealth's Equity

MDxHealth's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MDxHealth's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating MDxHealth's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

MDxHealth's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in MDxHealth’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about MDxHealth stock

The Equity of MDxHealth is -10.62 M USD in 2025.

The Equity of MDxHealth changed from 13.03 M USD to -10.62 M USD, representing a -181.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity MDxHealth since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's MDxHealth historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MDxHealth

All Key Metrics — MDxHealth